Amneal Pharmaceuticals (AMRX) to Release Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX) is scheduled to post its quarterly earnings results before the market opens on Friday, May 3rd. Analysts expect Amneal Pharmaceuticals to post earnings of $0.08 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.530-0.630 EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Friday, March 1st. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.07. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. The firm had revenue of $616.98 million for the quarter, compared to analyst estimates of $630.67 million. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock opened at $6.05 on Wednesday. The stock has a 50 day moving average of $5.72 and a two-hundred day moving average of $5.24. The company has a current ratio of 1.63, a quick ratio of 0.94 and a debt-to-equity ratio of 121.31. Amneal Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $6.46. The company has a market capitalization of $1.86 billion, a P/E ratio of -19.52 and a beta of 1.33.

Analyst Upgrades and Downgrades

AMRX has been the subject of a number of research reports. The Goldman Sachs Group raised their price objective on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the stock a “buy” rating in a research report on Monday, March 4th. Piper Sandler raised their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Barclays raised their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. Finally, StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 4th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $7.31.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.